Quick Answer
BioLineRx Ltd. reported Total Assets of $40.91 million for fiscal year 2025.
BioLineRx Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $40.91M +5.1% |
$38.91M -39.1% |
$63.92M -16.3% |
$76.38M -6.2% |
$81.39M +72.1% |
$47.29M -11.7% |
| R&D Expense | $8.09M -11.5% |
$9.15M -26.9% |
$12.52M -29.0% |
$17.63M -9.4% |
$19.47M +7.1% |
$18.17M -22.5% |
| Gross Profit | $950.0K -95.2% |
$19.68M +1675.9% |
$1.11M | $0.00 | $0.00 | — |
- BioLineRx Ltd. reported Total Assets of $40.91 million for fiscal year 2025.
- BioLineRx Ltd. showed an increase of +5.1% in Total Assets compared to the prior fiscal year.
- BioLineRx Ltd. reported R&D Expense of $8.09 million for fiscal year 2025.
- BioLineRx Ltd. showed a decrease of -11.5% in R&D Expense compared to the prior fiscal year.
- BioLineRx Ltd. reported Gross Profit of $950.0 thousand for fiscal year 2025.
- BioLineRx Ltd. showed a decrease of -95.2% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: